for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Teva Pharmaceutical Industries Limited

TEVA.TA

Latest Trade

3,940.00ILa

Change

83.00(+2.15%)

Volume

580,045

Today's Range

3,919.00

 - 

3,984.00

52 Week Range

2,175.00

 - 

4,709.00

As of on the Tel Aviv Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
3,857.00
Open
3,938.00
Volume
580,045
3M AVG Volume
27.11
Today's High
3,984.00
Today's Low
3,919.00
52 Week High
4,709.00
52 Week Low
2,175.00
Shares Out (MIL)
1,095.52
Market Cap (MIL)
43,213.73
Forward P/E
4.44
Dividend (Yield %)
--

Next Event

Q2 2020 Teva Pharmaceutical Industries Ltd Earnings Release

Latest Developments

More

FDA Says Teva Recalling 14 Lots Of Metformin Hydrochloride Extended-Release Tablets

National Institutes Of Health Begins Clinical Trial Of Hydroxychloroquine And Azithromycin To Treat Covid-19

Teva Reports Q1 Non-GAAP Earnings Per Share $0.76

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.

Industry

Biotechnology & Drugs

Contact Info

5 Bazel St, P O B 3190

49131

Israel

+972.3.9267267

http://www.tevapharm.com

Executive Leadership

Sol J. Barer

Independent Chairman of the Board

Kaare Schultz

President, Chief Executive Officer, Director

Eliyahu Sharon Kalif

Chief Financial Officer, Executive Vice President

Mark Sabag

Executive Vice President, Chief Human Resources Officer and Global Communications and Brand

Richard Daniell

Executive Vice President - European Commercial

Key Stats

2.50 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

22.4K

2018

18.9K

2020(E)

17.0K
EPS (USD)

2017

4.010

2019

-0.910

2020(E)

2.570
Price To Earnings (TTM)
--
Price To Sales (TTM)
0.74
Price To Book (MRQ)
0.92
Price To Cash Flow (TTM)
14.95
Total Debt To Equity (MRQ)
192.91
LT Debt To Equity (MRQ)
180.87
Return on Investment (TTM)
-2.00
Return on Equity (TTM)
-1.51

Latest News

Latest News

BRIEF-Teva Presents New Analyses Examining Changes In Migraine Disability Outcome Measurements With Ajovy Injection

* TEVA PRESENTS NEW ANALYSES EXAMINING CHANGES IN MIGRAINE DISABILITY OUTCOME MEASUREMENTS WITH AJOVY® (FREMANEZUMAB-VFRM) INJECTION

BRIEF-Teva To Present New Data On Ajovy Injection Open-Label Extension Study

* TEVA TO PRESENT NEW DATA ON AJOVY® (FREMANEZUMAB-VFRM) INJECTION OPEN-LABEL EXTENSION STUDY AT AMERICAN HEADACHE SOCIETY ANNUAL MEETING Source text for Eikon: Further company coverage:

BRIEF-Teva Pharmaceutical Shareholders Approve Amendment To Terms Of Office And Employment Of CEO

* TEVA PHARMACEUTICAL INDUSTRIES - SHAREHOLDERS APPROVED AMENDMENT NO. 1 TO TERMS OF OFFICE AND EMPLOYMENT OF CO'S CEO KÅRE SCHULTZ AT ANNUAL MEETING

EU antitrust regulators reinforce case against Teva pay-for-delay deals

EU antitrust enforcers, boosted by recent court victories, on Monday reinforced their case against Israeli drugmaker Teva over its deal with rival Cephalon to delay selling a generic version of its sleep disorder drug modafinil.

BRIEF-FDA Says Teva Recalling 14 Lots Of Metformin Hydrochloride Extended-Release Tablets

* US FDA SAYS TEVA RECALLING 14 LOTS OF METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS, USP 500 MG AND 750 MG, DUE TO DETECTION OF EXCESS NDMA LEVELS Source text : https://bit.ly/2zYnSAl Further company coverage:

Israel's Teva gets China approval for Huntington's treatment

Teva Pharmaceutical said on Monday that China has given the go-ahead to its Austedo treatment for Huntington's disease.

Teva Pharm gets approval in China for Huntington's treatment

China has given the greenlight to Teva Pharmaceutical Industries' Austedo treatment for Huntington's disease, the company said on Monday.

Teva Pharmaceutical's profit beats forecasts, shares jump

Israel-based Teva Pharmaceutical Industries <TEVA.TA> beat first-quarter profit forecasts on Thursday, boosted by stronger demand for generic and over-the-counter drugs and respiratory treatments.

BRIEF-Teva Reports Q1 Non-GAAP Earnings Per Share $0.76

* REVENUES FROM NORTH AMERICA SEGMENT IN Q1 OF 2020 WERE $2,082 MILLION, AN INCREASE OF $36 MILLION

Teva Pharm Q1 profit beats forecasts, reaffirms 2020 outlook

Israel-based Teva Pharmaceutical Industries reported a higher-than-expected rise in first-quarter profit on Thursday, boosted by stronger demand for generic and over-the-counter drugs and respiratory products.

BRIEF-Inhalation Sciences Sweden Signs Contract With Teva Pharmaceuticals

* INHALATION SCIENCES SIGNS CRO CONTRACT WORTH 30.5 KEUR WITH GLOBAL PHARMACEUTICAL COMPANY

BRIEF-Teva And Celltrion Healthcare Announce Launch Of TRUXIMA Injection

* TEVA AND CELLTRION HEALTHCARE ANNOUNCE LAUNCH OF TRUXIMA® (RITUXIMAB-ABBS) INJECTION FOR RHEUMATOID ARTHRITIS, ONLY BIOSIMILAR TO RITUXAN® (RITUXIMAB) AVAILABLE IN UNITED STATES FOR THIS INDICATION

BRIEF-Teva Announces U.S. Launch Of Autoinjector For AJOVY Injection

* TEVA ANNOUNCES U.S. LAUNCH OF AUTOINJECTOR FOR AJOVY® (FREMANEZUMAB-VFRM) INJECTION Source text for Eikon: Further company coverage:

U.S. court rules for Teva in migraine patent dispute with Eli Lilly

Teva Pharmaceutical Industries Ltd on Tuesday won a ruling from a U.S. administrative court that could help it fend off competition from Eli Lilly and Co in the market for migraine drugs.

U.S. court rules for Teva in migraine patent dispute with Eli Lilly

Teva Pharmaceutical Industries Ltd on Tuesday won a ruling from a U.S. administrative court that helps preserve its rights to the migraine drug Ajovy.

BRIEF-Teva Pharmaceutical Industries Says CEO Kåre Schultz's FY 2019 Total Compensation Was $11.6 Mln

* TEVA PHARMACEUTICAL INDUSTRIES LTD SAYS CEO KÅRE SCHULTZ'S FY 2019 TOTAL COMPENSATION WAS $11.6 MILLION VERSUS $32.5 MILLION IN FY 2018 - SEC FILING

BRIEF-Teva And Celltrion Healthcare Announce U.S. Availability Of Herzuma For Injection

* TEVA AND CELLTRION HEALTHCARE ANNOUNCE U.S. AVAILABILITY OF HERZUMA® (TRASTUZUMAB-PKRB) FOR INJECTION Source text for Eikon: Further company coverage:

BRIEF-Teva Announces FDA Approval Of Armonair Digihaler Inhalation Powder

* TEVA ANNOUNCES FDA APPROVAL OF ARMONAIR® DIGIHALER™ (FLUTICASONE PROPIONATE) INHALATION POWDER

Teva Pharm CEO hopes to launch Huntington's drug in China this year

Israel-based Teva Pharmaceutical Industries hopes to receive approval to launch its Huntington's treatment Austedo in China this year, the company's chief executive said on Wednesday.

Teva Pharm regains market trust amid restructuring

Teva Pharmaceutical Industries <TEVA.TA> <TEVA.N> said on Wednesday that a two-year restructuring has enabled the world's largest generic drugmaker to turn a corner, as it reported slightly better than expected fourth-quarter results.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up